PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Journal of Inherited Metabolic Disease Année : 2008

PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders

Résumé

Enzyme defects in the mitochondrial fatty acid oxidation (FAO) are a large family of inherited metabolic disease well characterized clinically and genetically, but for which pharmacological strategies remain limited. It is now well established that regulation of genes involved in mitochondrial FAO is under control of the PPAR (peroxisome proliferator activated receptor) signalling pathway, and this led us to test a possible pharmacological correction of FAO disorders by fibrates and other PPAR activators. This review presents the basic data supporting our initial hypothesis, summarizes the results obtained in cells from patients with CPT II (carnitine palmitoyltransfer-ase II) or VLCAD (very long-chain acyl-CoA dehydro-genase) deficiency, and discusses the perspectives and limits of this approach for therapy of these disorders. Abbreviations CPT II carnitine palmitoyltransferase II FALDH fatty aldehyde dehydrogenase FAO fatty acid oxidation PPAR peroxisome proliferator activated receptor RXR retinoid X receptor VLCAD very long-chain acyl-CoA dehydrogenase
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée
Loading...

Dates et versions

inserm-02896250 , version 1 (10-07-2020)

Identifiants

Citer

F. Djouadi, J. Bastin. PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders. Journal of Inherited Metabolic Disease, 2008, 31 (2), pp.217-225. ⟨10.1007/s10545-008-0844-7⟩. ⟨inserm-02896250⟩

Collections

INSERM CNRS
11 Consultations
1 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More